TD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Charles Rhyee maintains a Buy rating on GoodRx Holdings (NASDAQ:GDRX) and raises the price target from $14 to $16.
May 16, 2024 | 2:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen analyst Charles Rhyee maintains a Buy rating on GoodRx Holdings and raises the price target from $14 to $16.
The raised price target and maintained Buy rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100